Sarda Proteins Approves Major Corporate Shifts and Reports Quarterly Results

Sarda Proteins Approves Major Corporate Shifts and Reports Quarterly Results​

Sarda Proteins Ltd., on July 15, 2026, announced several significant outcomes from its Board meeting, including the approval of unaudited financial results for the quarter ended June 30, 2026. The board also greenlit key operational changes, such as a registered office relocation and the establishment of a new corporate office in Gujarat.

The company's Board of Directors held a meeting on July 15, 2026, during which multiple critical business matters were transacted. These actions included approving the Unaudited Standalone Financial Results (with Limited Review Reports) for the quarter ended June 30, 2026.

A major administrative decision approved by the board involved the relocation of the company’s registered office. The move shifts the location from B-536-537, Matsya Industrial Area, Alwar - 301030, Rajasthan, to a new address located at 2nd Floor, 2, Sai Collection Building, Bus Stand Road, Police Control Room, Alwar Bus Stand Area, Alwar, Rajasthan - 301001. The shift is effective from July 15, 2026 and remains within the local limits of Alwar, Rajasthan.

Furthermore, the board approved the establishment and commencement of a corporate office in Rajkot, Gujarat, with effect from July 15, 2026. The new corporate address is P-212 B, Gate No. 2, Lodhika GIDC, Rajkot, Metoda, Gujarat - 360021.

Governance and Appointments​

In a key governance decision, the company approved the appointment of Ms. Minal Surendra Jain as an Independent Women Director for a term of five consecutive years. This appointment, made at the meeting held on July 15, 2026, is subject to shareholder approval. Ms. Jain's profile includes extensive experience in corporate compliance and governance, focusing on regulatory compliances under the Companies Act, 2013, SEBI Regulations, and Stock Exchange requirements.

Additionally, the board members approved the reconstitution of three specialized committees: the Audit Committee, the Nomination and Remuneration Committee, and the Stakeholders' Relationship Committee, effective immediately.

Financial Performance Highlights (Q Ended June 30, 2026)​

Sarda Proteins presented a detailed financial performance review for the quarter ended June 30, 2026. The key figures from the Unaudited Standalone Financial Results are summarized below:


The financial results for the quarter ended June 30, 2026, showed total revenue of 1,847.40 Lakhs and a profit before tax (PBT) of 221.30 Lakhs. Total comprehensive income for the period was recorded at 165.97 Lakhs.

Independent Audit Review​

The Unaudited Standalone Financial Results were reviewed by A H Mandaliya & Associates, Chartered Accountants. The review concluded that nothing came to their attention that indicated that the accompanying Statement, prepared in accordance with Indian Accounting Standard (Ind AS) 34, had not disclosed the required information or contained any material misstatement.

Stock Price Movement​

At the close of trade, Sarda Proteins Ltd settled at ₹97.78, edging higher after posting a 4.99% gain. The shares registered completely flat throughout the session, as the intraday high and low were locked identically at ₹97.78.